Geron announces new data from IMerge

Geron announced new data and analyses from IMerge Phase 3 reporting robust durability of transfusion independence, or TI, evidence for disease-modifying activity and favorable fatigue patient-reported outcomes, or PRO, in lower risk myelodysplastic syndromes, or MDS, patients treated with the company’s first-in-class telomerase inhibitor, imetelstat, vs. placebo. The data and analyses were presented at the European Hematology Association annual meeting, which took place from June 8-11, 2023 in Frankfurt, Germany and virtually. Top-line results from the primary analysis of IMerge Phase 3 presented earlier this month at the 2023 American Society of Hematology, or ASCO, annual meeting were also covered in the EHA presentation, including the primary endpoint of eight-week transfusion independence and key secondary endpoint of 24-week TI were met with high statistical significance for imetelstat-treated patients vs. placebo. Further, mean hemoglobin levels in imetelstat-treated patients increased significantly over time compared to placebo patients. In addition to these results, the EHA presentation also provided new data and analyses highlighting clinically meaningful and durable TI for imetelstat-treated patients vs. placebo. As of a January 2023 data cut-off, 17.8% of imetelstat-treated patients vs. 1.7% of placebo-treated patients achieved 1-year TI, representing 63.6% of 24-week TI imetelstat responders. Two new analyses presented at EHA on TI responses by subgroups underscored the breadth of potential effect of imetelstat vs. placebo.